Insider Buying: Anixa Biosciences (NASDAQ:ANIX) Director Buys $30,400.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) Director Arnold Baskies acquired 10,000 shares of the firm’s stock in a transaction dated Wednesday, January 28th. The stock was bought at an average cost of $3.04 per share, with a total value of $30,400.00. Following the acquisition, the director owned 135,000 shares in the company, valued at approximately $410,400. This trade represents a 8.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Anixa Biosciences Stock Down 1.9%

Anixa Biosciences stock opened at $3.04 on Friday. The business’s 50-day moving average price is $3.64 and its 200 day moving average price is $3.59. The firm has a market cap of $101.48 million, a price-to-earnings ratio of -8.69 and a beta of 0.49. Anixa Biosciences Inc has a 52 week low of $2.33 and a 52 week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Monday, January 12th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Equities analysts expect that Anixa Biosciences Inc will post -0.41 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on ANIX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anixa Biosciences in a report on Monday, December 29th. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Friday, December 12th. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. Finally, Zacks Research lowered Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $9.00.

Hedge Funds Weigh In On Anixa Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP boosted its stake in shares of Anixa Biosciences by 378.4% in the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock worth $265,000 after acquiring an additional 63,584 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Anixa Biosciences by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock valued at $4,694,000 after purchasing an additional 29,436 shares in the last quarter. Citadel Advisors LLC lifted its holdings in Anixa Biosciences by 31.6% in the 3rd quarter. Citadel Advisors LLC now owns 96,010 shares of the company’s stock valued at $317,000 after purchasing an additional 23,072 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Anixa Biosciences during the 3rd quarter worth $51,000. Finally, World Investment Advisors purchased a new stake in shares of Anixa Biosciences during the third quarter worth $48,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.